Aztreonam vial
Dosage Adult: IV/IM Gm-ve infections 1-8 g/day in divided doses depending on severity. Max: 8 g/day. UTI 0.5-1 g 8-12 hrly. IM Cystitis; Gonorrhoea 1 g as a single dose.
Overdosage For action to be taken in the event of accidental overdose
Contraindications Hypersensitivity; lactation.
Special Precautions Hypersensitivity to other β-lactams; renal and hepatic impairment; pregnancy.
Adverse Drug Reactions IV: Phloebitis and thrombophloebitis. IM: Pain and swelling at inj site; diarrhoea, nausea, vomiting, altered taste; jaundice, hepatitis, high liver enzymes; long prothrombin time, partial thromboplastin time; rash, urticaria, eosinophilia.
Potentially Fatal: Thrombocytopenia, neutropenia; overgrowth of susceptible organisms; pseudomembranous colitis.
Drug Interactions Concurrent use with oral anticoagulants may increase prothrombin time.
AZENAM
Manufacturer Aristo
Contents aztreonam.
AZENAM vial
1 g x 1's (471.21 INR)
2 g x 1's (882.55 INR)
500 mg x 1's (310 INR)
.....................................................................................
Meropenem (MEROZA)
Dosage Adult: IV Susceptible infections 0.5-1 g 8 hrly. Meningitis 2 g 8 hrly. Cystic fibrosis Up to 2 g 8 hrly. Skin infections 500 mg 8 hrly. Diabetic foot; Intra-abdominal infections 1 g 8 hrly.
Overdosage For action to be taken in the event of accidental overdose
Contraindications Hypersensitivity.
Special Precautions History of hypersensitivity to carbapenem, pencillins or other β-lactam antibiotics; infants <3 mth; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA.
Adverse Drug Reactions Diarrhoea, nausea, vomiting, abdominal pain; headache; constipation; rash, pruritus, uticaria; apnoea; phlebitis, thrombophlebitis, swelling and pain at inj site; disturbances in LFTs (may cause increases in serum transaminases, alkaline phosphatase, lactic dehydrogenase). Rarely: erythema multiforme; eosinophilia, thrombocytopenia, leucopenia, neutropenia; seizures and CNS effects reported in patients with underlying CNS disorders or renal impairment.
Potentially Fatal: Anaphylaxis; pseudomembranous colitis; Stevens-Johnsons sydrome.
Drug Interactions: Serum levels may be increased by probenecid. May reduce serum valproic acid levels; sub-therapeutic levels may be reached in some patients.
Manufacturer Zydus (Alidac)
Contents meropenem.
MEROZA vial
1 g x 1's (2245 INR)
250 mg x 1's
500 mg x 1's (1194 INR)
………………………………………………………………………………………………
CILANEM (imipenem + cilastatin)
Dosage Adult: IV Susceptible infections As imipenem: 1-2 g/day in divided doses 6-8 hrly. Surgical prophylaxis As imipenem: 1 g on induction of anesth, followed by 1 g 3 hr later. Additional doses of 500 mg may be given at 8 and 16 hr after induction if needed. IM Susceptible infections As imipenem: 500 or 750 mg 12 hrly. Uncomplicated gonorrhoea As imipenem: 500 mg as single dose.
Indication & Dosage Intravenous
Susceptible infections
Adult: In terms of imipenem, 1-2 g daily in divided doses every 6-8 hr, given via IV infusion. Doses 250 or 500 mg are infused over 20-30 minutes, and doses of 750 mg or 1 g over 40-60 minutes.
Child: >40 kg: same as adult dose. >3 mth and <40 kg: 15-25 mg/kg every 6 hr by IV infusion. Up to 90 mg/kg may be given to older children with cystic fibrosis. Neonates and infants <3 mth: 4 wk-3 mth, 25 mg/kg every 6 hr; 1-4 wk, 25 mg/kg every 8 hr; up to 1 wk, 25 mg/kg every 12 hr.
Max Dosage: Adults and children >40 kg: 4 g/day or 50 mg/kg. Children <40 kg: 2 g/day.
Intravenous
Prophylaxis of surgical infections
Adult: In terms of imipenem, 1 g given on induction of anaesthesia, followed by 1 g 3 hr later, with additional doses of 500 mg at 8 and 16 hr after induction if necessary.
Intramuscular
Mild to moderate susceptible infections
Adult: In terms of imipenem, 500 mg or 750 mg every 12 hr.
Intramuscular
Uncomplicated gonorrhea
Adult: In terms of imipenem: A single 500 mg dose may be used. Contraindications Hypersensitivity. Special Precautions
Caution when used in patients with known hypersensitivity to other β-lactams due to possibility of cross-sensitivity. CNS disorders such as epilepsy; renal, hepatic impairment; pregnancy, lactation. Adverse Drug Reactions Skin rashes, urticaria, eosinophilia, fever, nausea, vomiting, diarrhoea, tooth or tongue discoloration and altered taste. Erythema multiforme, exfoliative dermatitis. Pain and thrombophlebitis may occur at the inj site.Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis. Mechanism of Action Imipenem is a potent inhibitor of bacterial cell wall synthesis and is bactericidal against a broad spectrum of pathogens. It is resistant to degradation by bacterial β-lactamases. Cilastatin is an inhibitor of dehydropeptidase I, an enzyme found in the brush border of the renal tubules. It is given as the sodium salt with imipenem to prevent its renal metabolism and protect against nephrotoxic effects.
Absorption: IM admin: 60-75% (imipenem); 95-100% (cilastatin).
Distribution: Rapidly and widely distributed to most tissues and fluids. Protein binding: 20% (imipenem) and 40% (cilastatin).
Metabolism: Imipenem: Metabolised renally by dehydropeptidase I; cilastatin: Partly metabolised renally.
Excretion: Via urine (about 70% as unchanged drug). Half-life: 2-3 hr (imipenem after IM admin).
Manufacturer Ranbaxy
Contents CILANEM vial: imipenem 250 mg, cilastatin sodium 250 mg.
CILANEM vial: imipenem 500 mg, cilastatin sodium 500 mg.
CILANEM vial 1's (668.12 INR)
CILANEM vial 1's (1113 INR)
……………………………………………………………………..